Presenting_features_and_prognosis_of_chronic_lymphocytic_leukemia_in_younger_adults._We_have_analyzed_117_younger_patients_with_chronic_lymphocytic_leukemia_(CLL)_(mean_age,_44.5_years;_SD,_4.8;_range,_19_to_49;_male/female_ratio,_2.08)_with_three_main_objectives:_(1)_to_see_whether_these_patients_have_distinctive_presenting_clinical_features;_(2)_to_investigate_the_impact_of_the_disease_on_survival;_and_(3)_to_analyze_whether_already_well-known_prognostic_factors_are_also_useful_when_applied_to_these_patients._As_compared_with_an_older_age_population_(greater_than_or_equal_to_50_years),_there_were_no_major_differences_in_presenting_features_except_for_an_increased_proportion_of_males_(2.08_v_1.21;_P_less_than_.025)_and_a_higher_hemoglobin_level_(13.47_+/-_2.70_g/dL_v_12.84_+/-_2.77_g/dL;_P_less_than_.05)_in_the_younger_group._Median_survival_is_12.3_years_(expected_median_from_a_control_group,_31.2_years)._Clinical_stages,_bone_marrow_patterns,_blood_lymphocyte_counts,_and_its_doubling_time_are_all_useful_to_separate_different_risk_groups_of_patients._Whereas_patients_with_favorable_prognostic_factors_have_a_survival_probability_of_about_80%_14_years_after_diagnosis,_those_with_poor_prognostic_features_have_a_median_survival_of_less_than_3_years._It_is_concluded_that_CLL_in_younger_adults_has_no_major_distinctive_presenting_features_and_that_known_prognostic_factors_are_useful_to_separate_different_risk_groups_of_patients._These_results_should_be_of_help_in_planning_therapy_for_younger_persons_with_CLL.